Such a morphological and cellular alteration in lungs with EGR2-deficient AMs was more obviously detected in pathogen-activated inflammatory cells of either AF or zymosan-treated pulmonary tissues (Figure 8H). The gene discussed is EGR2; the disease is atrial fibrillation.